HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO HeMo Bioengineering - Insights on Industry, Business and Concerns

China Healthcare Weekly (Feb.4)- "14th Five-Year Plan" Of Pharmaceuticals, the Right Way to Innovate

Interpretation of The "14th Five-Year Plan" For the Development of China Pharmaceutical Industry

Peijia Medical (9996.HK) Vs Venus MedTech (2500.HK) Vs CardioFlow (2160.HK)-Pain Points and Solution

The Insecure Rebound in Healthcare Sector and the Future Direction of Stock Price (2022)

A Second Thought on the License-In Mode - Dilemmas and Solutions

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Thematic (Sector/Industry)

Hong kong Pharmaceuticals, biotechnology and life sciences / Thematic (Sector/Industry)

<ul>
<li>Last week, the 7th national volume-based purchase (VBP) began, involving 208 product specifications and 59 varieties.</li>
<li>We summaries the competitive landscape and outlook of both domestic and foreign pharmaceutical companies in this VBP.</li>
<li>Most investors may not have experienced July 22, 2015, so there is no reason to dismiss the prospects of China's healthcare industry because of the correction in the short term. </li>
</ul>


Last week, the 7th national volume-based purchase (VBP) began, involving 208 product specifications and 59 varieties.
We summaries the competitive landscape and outlook of both domestic and foreign pharmaceutical companies in this VBP.
Most investors may not have experienced July 22, 2015, so there is no reason to dismiss the prospects of China's healthcare industry because of the correction in the short term. 


Shanghai MicroPort MedBot Group (2252 HK)

China Healthcare Weekly (Jan.28) - 7th National VBP, Taking History as a Mirror, Confidence Rebuilt